TITLE

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

AUTHOR(S)

Shames, David S.; Carbon, Juliet; Walter, Kim; Jubb, Adrian M.; Kozlowski, Cleopatra; Januario, Tom; An, Do; Fu, Ling; Xiao, Yuanyuan; Raja, Rajiv; Jiang, Brittany; Malekafzali, Ashi; Stern, Howard; Settleman, Jeff; Wilson, Timothy R.; Hampton, Garret M.; Yauch, Robert L.; Pirzkall, Andrea; Amler, Lukas C.

PUB. DATE

February 2013

SOURCE

PLoS ONE;Feb2013, Vol. 8 Issue 2, p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Purpose: Tumors with oncogenic dependencies on the HER family of receptor tyrosine kinases (RTKs) often respond well to targeted inhibition. Our previous work suggested that many cell lines derived from squamous cell carcinomas of the head and neck (SCCHNs) depend on autocrine signaling driven by HER2/3 dimerization and high-level co-expression of HRG. Additionally, results from a Phase I trial of MEHD7495A, a dual-action antibody that blocks ligand binding to EGFR and HER3, suggest that high-level HRG expression was associated with clinical response in SCCHN patients. Here we explore the hypothesis that high-level HRG expression defines a subpopulation of SCCHNs with activated HER3. Experimental Design: qRT-PCR expression profiling was performed on >750 tumors of diverse origin, including >150 therapy-naïve, primary, and recurrent SCCHNs. Activated HER3, defined by immunoprecipitation of phospho-HER3, was compared to HRG expression in SCCHN samples. Paracrine versus autocrine expression was evaluated using RNA-in situ hybridization. Results: SCCHN tumors express the highest levels of HRG compared to a diverse collection of other tumor types. We show that high HRG expression is associated with activated HER3, whereas low HRG expression is associated with low HER3 activation in SCCHN tumors. Furthermore, HRG expression is higher in recurrent SCCHN compared to patient-matched therapy naïve specimens. Conclusions: HRG expression levels define a biologically distinct subset of SCCHN patients. We propose that high-level expression of HRG is associated with constitutive activation of HER3 in SCCHN and thus defines an actionable biomarker for interventions targeting HER3.

ACCESSION #

87624908

 

Related Articles

• Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Carles, A; Millon, R; Cromer, A; Ganguli, G; Lemaire, F; Young, J; Wasylyk, C; Muller, D; Schultz, I; Rabouel, Y; Dembélé, D; Zhao, C; Marchal, P; Ducray, C; Bracco, L; Abecassis, J; Poch, O; Wasylyk, B // Oncogene;3/16/2006, Vol. 25 Issue 12, p1821 

  Head and neck squamous cell carcinoma (HNSCC) is common worldwide and is associated with a poor rate of survival. Identification of new markers and therapeutic targets, and understanding the complex transformation process, will require a comprehensive description of genome expression, that can...

• Cyclin A1 shows age-related expression in benign tonsils, HPV16-dependent overexpression in HNSCC and predicts lower recurrence rate in HNSCC independently of HPV16.  // BMC Cancer;2012, Vol. 12 Issue 1, p259 

  The article discusses a study conducted to establish the impact of tumor suppressor gene "Cyclin A1" expression on clinicopathological parameters in Head and Neck Squamous Cell Carcinoma (HNSCC). It has been informed that the study also tries to re-evaluate the relationship between Human...

• Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: A pathway-based analysis. Hensen, Erik F.; De Herdt, Maria J.; Goeman, Jelle J.; Oosting, Jan; Smit, Vincent T. H. B. M.; Cornelisse, Cees J.; Baatenburg de Jong, Robert J. // BMC Cancer;2008, Vol. 8, Special section p1 

  Background: Regional lymph node metastasis is an important prognostic factor in head and neck squamous cell carcinoma (HNSCC) and plays a decisive role in the choice of treatment. Here, we present an independent gene expression validation study of metastasized versus non-metastasized HNSCC....

• Targeted therapy: A novel approach in head and neck cancer. A., Winnifred Christy; Bojan, Anitha // Indian Journal of Dental Research;Mar/Apr2013, Vol. 24 Issue 2, p261 

  The majority of patients with head and neck cancer present with locally advanced disease. Locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) poses one of the most complex management challenges. This stage of disease is still potentially curable, but requires...

• Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Schirosi, L.; Nannini, N.; Nicoli, D.; Cavazza, A.; Valli, R.; Buti, S.; Garagnani, L.; Sartori, G.; Calabrese, F.; Marchetti, A.; Buttitta, F.; Felicioni, L.; Migaldi, M.; Rea, F.; Di Chiara, F.; Mengoli, M. C.; Rossi, G. // Annals of Oncology;Sep2012, Vol. 23 Issue 9, p2409 

  Background To analyze a multi-institutional series of type C thymic carcinomas (TCs) (including neuroendocrine tumors), focusing on the expression and mutations of c-KIT. Materials and methods Immunohistochemical expression of c-KIT/CD117, p63, CD5 and neuroendocrine markers, as well as...

• Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Minkyu Jung; Se Hyun Kim; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho // Yonsei Medical Journal;Sep2012, Vol. 53 Issue 5, p931 

  Purpose: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with geitinib or erlotinib. Materials and Methods: Pretreatment CEA...

• Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. WEMMERT, SILKE; LINDNER, YASMIN; LINXWEILER, JOHANNES; WAGENPFEIL, STEFAN; BOHLE, RAINER; NIEWALD, MARCUS; SCHICK, BERNHARD // Oncology Letters;Mar2016, Vol. 11 Issue 3, p1661 

  Head and neck squamous cell carcinoma (HNSCC) is a malignancy with an increasing incidence. To aid with the selection of the most appropriate therapy, biomarkers have become a specific research focus. Sec62 is involved in endoplasmic reticulum stress tolerance and cell migration, and has been...

• Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Tan, Nguyen; West, Kristina; McArthur, Grant; Toner, Guy C.; Manning, William C.; Smolich, Beverly D.; Cherrington, Julie M.; Morimoto, Alyssa M. // Oncogene;2/26/2004, Vol. 23 Issue 8, p1618 

  Biomarkers that indicate biological activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclinical development in order to impact decision-making during early clinical...

• Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Gehrmann, Mathias; Specht, Hanno M.; Bayer, Christine; Brandstetter, Markus; Chizzali, Barbara; Duma, Marciana; Breuninger, Stephanie; Hiller, Julia; Hube, Kathrin; Lehnerer, Sophie; Phi, Valerie van; Sage, Eva; Schmid, Thomas E.; Sedelmayr, Michael; Schilling, Daniela; Sievert, Wolfgang; Stangl, Stefan; Bier, Henning; Multhoff, Gabriele // Radiation Oncology;2014, Vol. 9 Issue 1, p1 

  Background Tumor but not normal cells frequently overexpress heat shock protein 70 (Hsp70) and present it on their cell surface (mHsp70) from where it can be actively released. Therefore, membrane (mHsp70) and soluble Hsp70 (sHsp70) were investigated as potential tumor biomarkers and for...

Read the Article